Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2016

  • ID: 3734774
  • Report
  • 438 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • BioLineRx, Ltd.
  • Cellceutix Corporation
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Novartis AG
  • MORE
Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2016

Summary

‘Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2016’, provides an overview of the Relapsed Acute Myeloid Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Relapsed Acute Myeloid Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsed Acute Myeloid Leukemia and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia
- The report reviews pipeline therapeutics for Relapsed Acute Myeloid Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Relapsed Acute Myeloid Leukemia therapeutics and enlists all their major and minor projects
- The report assesses Relapsed Acute Myeloid Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Relapsed Acute Myeloid Leukemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • BioLineRx, Ltd.
  • Cellceutix Corporation
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Relapsed Acute Myeloid Leukemia Overview

Therapeutics Development

Pipeline Products for Relapsed Acute Myeloid Leukemia - Overview

Pipeline Products for Relapsed Acute Myeloid Leukemia - Comparative Analysis

Relapsed Acute Myeloid Leukemia - Therapeutics under Development by Companies

Relapsed Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes

Relapsed Acute Myeloid Leukemia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Relapsed Acute Myeloid Leukemia - Products under Development by Companies

Relapsed Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes

Relapsed Acute Myeloid Leukemia - Companies Involved in Therapeutics Development

4SC AG

AbbVie Inc.

Actinium Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Amgen Inc.

Arog Pharmaceuticals, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

AVEO Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

BioLineRx, Ltd.

BioSight Ltd.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Celgene Corporation

Cellceutix Corporation

Cornerstone Pharmaceuticals, Inc.

CTI BioPharma Corp.

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

EpiZyme, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

FORMA Therapeutics, Inc.

Fujifilm Corporation

GlaxoSmithKline Plc

GlycoMimetics, Inc.

Igenica Biotherapeutics, Inc.

Incyte Corporation

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Johnson & Johnson

JW Pharmaceutical Corporation

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Les Laboratoires Servier SAS

MacroGenics, Inc.

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

NantKwest, Inc.

Novartis AG

Oxford BioTherapeutics Ltd

Pfizer Inc.

Pharma Mar, S.A.

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Sunesis Pharmaceuticals, Inc.

TaiGen Biotechnology Co., Ltd.

Tolero Pharmaceuticals, Inc.

Verastem, Inc.

Relapsed Acute Myeloid Leukemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

4SC-202 - Drug Profile

AG-120 - Drug Profile

AG-881 - Drug Profile

alvocidib hydrochloride - Drug Profile

AMG-232 - Drug Profile

AMG-330 - Drug Profile

aNK Program - Drug Profile

APTA-16 - Drug Profile

BI-836858 - Drug Profile

binimetinib - Drug Profile

BL-8040 - Drug Profile

bortezomib - Drug Profile

BPX-701 - Drug Profile

BST-236 - Drug Profile

buparlisib hydrochloride - Drug Profile

burixafor - Drug Profile

cabozantinib s-malate - Drug Profile

cafusertib hydrochloride - Drug Profile

CB-839 - Drug Profile

CC-90007 - Drug Profile

Cellular Immunotherapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia - Drug Profile

Cellular Immunotherapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia - Drug Profile

Cellular Immunotherapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile

Cellular Immunotherapy to Target WT-1, NY-ESO-1, PRAME and Survivin for Oncology - Drug Profile

CPI-613 - Drug Profile

crenolanib besylate - Drug Profile

CWP-291 - Drug Profile

DFP-10917 - Drug Profile

DS-3032 - Drug Profile

E-6201 - Drug Profile

eltrombopag olamine - Drug Profile

erlotinib hydrochloride - Drug Profile

FF-10501 - Drug Profile

ficlatuzumab - Drug Profile

FLX-925 - Drug Profile

FT-1101 - Drug Profile

gedatolisib - Drug Profile

gilteritinib fumarate - Drug Profile

GMI-1271 - Drug Profile

GO-2032c - Drug Profile

GSK-2879552 - Drug Profile

GSK-525762 - Drug Profile

Hu8F4 - Drug Profile

HXR-9 - Drug Profile

IGN-523 - Drug Profile

imatinib mesylate - Drug Profile

indisulam - Drug Profile

Iomab-B - Drug Profile

JNJ-63709178 - Drug Profile

KHK-2823 - Drug Profile

KM-3174 - Drug Profile

lenalidomide - Drug Profile

lirilumab - Drug Profile

lurbinectedin - Drug Profile

MGD-006 - Drug Profile

MK-2206 - Drug Profile

napabucasin - Drug Profile

Oshadi D + Oshadi R - Drug Profile

OX-001 - Drug Profile

pegargiminase - Drug Profile

PIM-447 - Drug Profile

pinometostat - Drug Profile

PLX-51107 - Drug Profile

quizartinib dihydrochloride - Drug Profile

RG-6146 - Drug Profile

RG-7775 - Drug Profile

ruxolitinib phosphate - Drug Profile

S-055746 - Drug Profile

selinexor - Drug Profile

TAK-659 - Drug Profile

tigecycline - Drug Profile

tosedostat - Drug Profile

ulocuplumab - Drug Profile

vadastuximab talirine - Drug Profile

venetoclax - Drug Profile

vorinostat - Drug Profile

vosaroxin - Drug Profile

VS-4718 - Drug Profile

Relapsed Acute Myeloid Leukemia - Recent Pipeline Updates

Relapsed Acute Myeloid Leukemia - Dormant Projects

Relapsed Acute Myeloid Leukemia - Discontinued Products

Relapsed Acute Myeloid Leukemia - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Relapsed Acute Myeloid Leukemia, H1 2016

Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Investigation by Universities/Institutes, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by 4SC AG, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Amgen Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by BioLineRx, Ltd., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by BioSight Ltd., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Boston Biomedical, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Cellceutix Corporation, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by GlycoMimetics, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Johnson & Johnson, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by NantKwest, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Novartis AG, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Pfizer Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Pharma Mar, S.A., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016

Relapsed Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Relapsed Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H1 2016

Relapsed Acute Myeloid Leukemia - Dormant Projects, H1 2016

Relapsed Acute Myeloid Leukemia - Dormant Projects (Contd..1), H1 2016

Relapsed Acute Myeloid Leukemia - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Relapsed Acute Myeloid Leukemia, H1 2016

Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
4SC AG
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Amgen Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
AVEO Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
BioLineRx, Ltd.
BioSight Ltd.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cellceutix Corporation
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
EpiZyme, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FORMA Therapeutics, Inc.
Fujifilm Corporation
GlaxoSmithKline Plc
GlycoMimetics, Inc.
Igenica Biotherapeutics, Inc.
Incyte Corporation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Johnson & Johnson
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
MacroGenics, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
NantKwest, Inc.
Novartis AG
Oxford BioTherapeutics Ltd
Pfizer Inc.
Pharma Mar, S.A.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Sunesis Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
Tolero Pharmaceuticals, Inc.
Verastem, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll